Nanotech 2011

Dendrimers: New Opportunities to Treat and Prevent Human Disease

D.J. Owen
Starpharma Pty Ltd, AU

Keywords: dendrimer, drug delivery, cancer

Abstract:

Starpharma dendrimers are a class of well defined, synthetic macromolecules which have already been successfully tested in human trails as part of the development of Starpharma’s lead product Vivagel®. Vivagel® is a microbicide in development under two FDA INDs for the prevention of HIV and Genital Herpes and has already attracted significant support from the National Institutes of Heath (NIH) to assist in bringing it to the market. As well as being drugs in their own right, Starpharma’s dendrimers can be used to modify the properties of other drugs. Drug delivery and drug optimization techniques are increasingly recognized as key to the enhancement of new drugs and drug life cycle management. Starpharma’s development programs are particularly aimed at improving the delivery and pharmacokinetic properties for a number of different classes of target molecules, for example, small-molecule anticancer agents, biologicals (eg. peptides & proteins) and oligonucleotides. This presentation will provide an overview of the current programs being undertaken at Starpharma, and will provide recent results from our cancer program.
 

TechConnect World 2011 Nanotech 2011 Clean Technology 2011 Microtech 2011 BioNanotech 2011 TechConnect Summit 2011
Program | Tracks | Exhibition | Press | Venue | Register |
Symposia | Short Courses | News | Subscribe | Contact | Site Map
© Copyright 2010 TechConnect World. All Rights Reserved.